FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

Apoptosis

Volumn 18, Issue 11, 2013, Pages 1437-1446

  Kiyota, Miki ^a   Kuroda, Junya ^a   Yamamoto Sugitani, Mio ^a   Shimura, Yuji ^a   Nakayama, Ryuko ^a   Nagoshi, Hisao ^a   Mizutani, Shinsuke ^a   Chinen, Yoshiaki ^a   Sasaki, Nana ^a   Sakamoto, Natsumi ^a   Kobayashi, Tsutomu ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; BID; BIM; Chronic myelogenous leukemia; FTY720

Indexed keywords

ABELSON KINASE; ACTIN; BH3 PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FINGOLIMOD; GALECTIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL KILLING; CELL PROTECTION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-ASSOCIATED DEATH PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; MUTATION; PRIMARY CELL CULTURE; PROPYLENE GLYCOLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84886432489     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0882-y     Document Type: Article

References (60)

1. O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004
2. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 362:2260-2270
3. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259
4. Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N, Taniwaki M (2013) Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. Curr Cancer Drug Targ 13:69-79
5. Kuroda J, Puthalakath H, Cragg MS et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907-14912
6. Kuroda J, Kimura S, Strasser A et al (2007) Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 14:1667-1677
7. Skaggs BJ, Gorre ME, Ryvkin A et al (2006) Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103:19466-19471
8. Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880
9. Yamamoto-Sugitani M, Kuroda J, Ashihara E et al (2011) Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 108:17468-17473
10. Kamitsuji Y, Kuroda J, Kimura S et al (2008) The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ 15:1712-1722
11. Bellodi C, Lidonnici MR, Hamilton A et al (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119:1109-1123
12. Crowley LC, Elzinga BM, O'Sullivan GC, McKenna SL (2011) Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol 86:38-47
13. Jørgensen HG, Holyoake TL (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 35:1347-1351
14. Jamieson CH, Ailles LE, Dylla SJ et al (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657-667
15. Lemoli RM, Salvestrini V, Bianchi E et al (2009) Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 114:5191-5200
16. Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532-4539
17. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121:396-409
18. Takeuchi M, Kimura S, Kuroda J et al (2010) Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 17:1211-1220
19. Schmidt T, Kharabi Masouleh B, Loges S et al (2011) Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 19:740-753
20. Damiano JS, Hazlehurst LA, Dalton WS (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15:1232-1239
21. Jin L, Tabe Y, Konoplev S et al (2008) CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7:48-58
22. Wang Y, Cai D, Brendel C et al (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109:2147-2155
23. Ng KP, Hillmer AM, Chuah CT et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521-528
24. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117:6660-6668
25. Mahon FX, Réa D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029-1035
26. Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719-1724
27. Stamatović D, Balint B, Tukić L et al (2012) Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy. Vojnosanit Pregl 69:37-42
28. Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417-439
29. Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34-41
30. Azuma H, Takahara S, Ichimaru N et al (2002) Marked Prevention of Tumor Growth and Metastasis by a Novel Immunosuppressive Agent, FTY720, in Mouse Breast Cancer Models. Cancer Res 62:1410-1419
31. Calin GA, di Iasio MG, Caprini E et al (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19:1191-1195
32. Suzuki K, Takahashi K (2003) Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. Int J Oncol 23:1263-1268
33. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S (2000) Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 47:268-271
34. Neviani P, Santhanam R, Trotta R et al (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8:355-368
35. Kappos L, Antel J, Comi G et al (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140
36. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
37. Devonshire V, Havrdova E, Radue EW et al (2012) Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 11:420-428
38. Brinkmann V, Davis MD, Heise CE et al (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457
39. Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349
40. Matloubian M, Lo CG, Cinamon G et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360
41. Neviani P, Santhanam R, Oaks JJ et al (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117:2408-2421
42. Liao A, Broeg K, Fox T et al (2011) Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 118:2793-2800
43. Liu Q, Zhao X, Frissora F et al (2008) FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111:275-284
44. Liu Q, Alinari L, Chen CS et al (2010) FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 16:3182-3192
45. Roberts KG, Smith AM, McDougall F et al (2010) Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 70:5438-5447
46. Shinomiya T, Li XK, Amemiya H, Suzuki S (1997) An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60. Immunology 91:594-600
47. Permpongkosol S, Wang JD, Takahara S et al (2002) Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 98:167-172
48. Brinkmann V, Wilt C, Kristofic C et al (2001) FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 33:3078-3080
49. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616
50. Suzuki E, Handa K, Toledo MS, Hakomori S (2004) Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sci USA 101:14788-14793
51. Shimura Y, Kuroda J, Ri M et al (2012) RSK2Ser227 at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther 11:2600-2609
52. Ricci C, Scappini B, Divoky V et al (2002) Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 62:5995-5998
53. Kuroda J, Taniwaki M (2009) Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol 71:89-101
54. Kuwana T, Bouchier-Hayes L, Chipuk JE et al (2005) BH3 domeins of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17:525-535
55. Willis SN, Fletcher JI, Kaufmann T et al (2007) Apopotosis initiated when BH3 ligands engage multiple Bcl-2 homologys, not Bax or Bak. Science 315:856-859
56. Kuroda J, Kimura S, Andreeff M et al (2008) ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140:181-190
57. Burke BA, Carroll M (2010) BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 24:1105-1112
58. San José-Eneriz E, Agirre X, Jiménez-Velasco A et al (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 45:1877-1889
59. Kuroda J, Yamamoto M, Nagoshi H et al (2010) Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8:994-1001
60. Česen MH, Pegan K, Spes A, Turk B (2012) Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318:1245-1251